First-line treatment of metastatic castration-resistant prostate cancer associated with a BRCA mutation

Males with advanced prostate cancer who have evidence of disease progression (eg, an increase in serum prostate-specific antigen [PSA], new metastases, or progression of existing metastases) and who have castrate levels of serum testosterone (<50 ng/dL) are considered to have castration-resistant prostate cancer (CRPC).